Cigna Group $CI Shares Acquired by Global Wealth Management Investment Advisory Inc.

Global Wealth Management Investment Advisory Inc. increased its stake in shares of Cigna Group (NYSE:CI) by 3.5% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 8,536 shares of the health services provider’s stock after purchasing an additional 289 shares during the period. Global Wealth Management Investment Advisory Inc.’s holdings in Cigna Group were worth $2,822,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Valeo Financial Advisors LLC raised its holdings in shares of Cigna Group by 86,071.1% during the second quarter. Valeo Financial Advisors LLC now owns 3,475,282 shares of the health services provider’s stock valued at $1,148,859,000 after acquiring an additional 3,471,249 shares during the last quarter. Nuveen LLC purchased a new stake in shares of Cigna Group during the first quarter worth approximately $727,905,000. Price T Rowe Associates Inc. MD increased its position in shares of Cigna Group by 10.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 12,056,806 shares of the health services provider’s stock worth $3,966,690,000 after purchasing an additional 1,094,327 shares in the last quarter. GQG Partners LLC raised its stake in Cigna Group by 21.5% in the 1st quarter. GQG Partners LLC now owns 4,886,674 shares of the health services provider’s stock valued at $1,607,716,000 after purchasing an additional 865,092 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its holdings in Cigna Group by 38.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,649,837 shares of the health services provider’s stock valued at $542,796,000 after purchasing an additional 457,052 shares in the last quarter. 86.99% of the stock is owned by hedge funds and other institutional investors.

Cigna Group Trading Up 3.2%

Shares of Cigna Group stock opened at $264.54 on Friday. The stock has a 50 day moving average of $293.24 and a 200 day moving average of $303.54. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.71 and a current ratio of 0.71. The firm has a market capitalization of $70.66 billion, a price-to-earnings ratio of 14.44, a PEG ratio of 0.88 and a beta of 0.44. Cigna Group has a fifty-two week low of $239.51 and a fifty-two week high of $350.00.

Cigna Group (NYSE:CI) last released its quarterly earnings results on Thursday, October 30th. The health services provider reported $7.83 earnings per share for the quarter, topping analysts’ consensus estimates of $7.64 by $0.19. The business had revenue of $69.57 billion during the quarter, compared to analysts’ expectations of $66.40 billion. Cigna Group had a return on equity of 18.80% and a net margin of 1.92%.The company’s revenue was up 9.5% compared to the same quarter last year. During the same period in the prior year, the business posted $7.51 EPS. Cigna Group has set its FY 2025 guidance at 29.600- EPS. As a group, research analysts predict that Cigna Group will post 29.77 earnings per share for the current year.

Cigna Group Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 18th. Shareholders of record on Thursday, December 4th will be given a dividend of $1.51 per share. The ex-dividend date is Thursday, December 4th. This represents a $6.04 dividend on an annualized basis and a dividend yield of 2.3%. Cigna Group’s dividend payout ratio (DPR) is currently 26.64%.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on CI. Jefferies Financial Group reaffirmed a “buy” rating and set a $310.00 target price on shares of Cigna Group in a report on Monday, November 3rd. Cowen restated a “buy” rating on shares of Cigna Group in a research report on Tuesday. Leerink Partners cut their price objective on shares of Cigna Group from $300.00 to $270.00 in a report on Friday, October 31st. TD Cowen decreased their target price on shares of Cigna Group from $387.00 to $333.00 and set a “buy” rating on the stock in a research note on Tuesday, November 4th. Finally, Guggenheim dropped their price target on Cigna Group from $350.00 to $309.00 in a research report on Friday, October 31st. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Cigna Group presently has a consensus rating of “Moderate Buy” and a consensus price target of $339.73.

Insider Activity

In other news, CEO David Cordani bought 4,134 shares of the business’s stock in a transaction on Monday, November 3rd. The shares were bought at an average price of $241.88 per share, with a total value of $999,931.92. Following the completion of the transaction, the chief executive officer directly owned 157,935 shares in the company, valued at $38,201,317.80. This trade represents a 2.69% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Nicole S. Jones sold 28,526 shares of the company’s stock in a transaction on Friday, August 15th. The stock was sold at an average price of $300.00, for a total value of $8,557,800.00. Following the transaction, the insider owned 25,648 shares in the company, valued at $7,694,400. This trade represents a 52.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.70% of the company’s stock.

Cigna Group Profile

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers.